Biggest changeThe following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2022 2021 2020 Dollars Dollars Dollars Net revenues: Commission $ 341,467 $ 881,263 $ 671,140 Enterprise 290,208 181,152 206,210 Net revenues 631,675 1,062,415 877,350 Operating expenses: Cost of revenue 187,670 239,335 199,202 Marketing and advertising expense 207,559 365,141 206,864 Customer care and enrollment 260,902 319,103 165,497 Technology expense 46,094 48,429 59,348 General and administrative 116,530 98,183 197,229 Amortization of intangible assets 94,057 94,056 94,056 Operating lease impairment charges 25,345 1,062 — Restructuring and other related charges 12,184 — — Goodwill impairment charges — 386,553 — Change in fair value of contingent consideration liability — — 19,700 Total operating expenses 950,341 1,551,862 941,896 Income (loss) from operations (318,666) (489,447) (64,546) Interest expense 57,069 33,505 32,969 Loss on extinguishment of debt — 11,935 — Other (income) expense, net (115) (669) (358) Income (loss) before income taxes (375,620) (534,218) (97,157) Income tax expense (benefit) 764 (24) 43 Net income (loss) $ (376,384) $ (534,194) (97,200) Net income (loss) attributable to noncontrolling interests (227,678) (344,837) (52,933) Net income (loss) attributable to GoHealth, Inc. $ (148,706) $ (189,357) $ (44,267) Non-GAAP financial measures: EBITDA $ (211,549) $ (393,206) $ 34,364 Adjusted EBITDA $ (129,776) $ 33,821 $ 271,029 Adjusted EBITDA margin (20.5) % 3.2 % 30.9 % The following are our components of net revenue and results thereof for the twelve months ended December 31, 2022 and 2021: Commission net revenues Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 341,467 $ 881,263 $ (539,796) (61.3) % 54.1% 82.9% The $539.8 million, or 61.3% decrease was primarily attributable to reduced agent headcount and lower penetration through commissions revenue in the Medicare-Internal segment, which reflects the expansion of the Encompass Solution within enterprise revenue.
Biggest changeThe following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2023 2022 2021 Net revenues $ 734,671 $ 631,675 $ 1,062,415 Operating expenses: Revenue share 158,961 187,670 239,335 Marketing and advertising expense 205,042 207,559 365,141 Customer care and enrollment 209,234 260,902 319,103 Technology expense 43,302 46,094 48,429 General and administrative 93,069 116,530 98,183 Amortization of intangible assets 94,057 94,057 94,056 Operating lease impairment charges 2,687 25,345 1,062 Restructuring and other related charges — 12,184 — Goodwill and intangible asset impairment charges 10,000 — 386,553 Total operating expenses 816,352 950,341 1,551,862 Income (loss) from operations (81,681) (318,666) (489,447) Interest expense 69,472 57,069 33,505 Loss on extinguishment of debt — — 11,935 Other (income) expense, net (37) (115) (669) Income (loss) before income taxes (151,116) (375,620) (534,218) Income tax expense (benefit) 154 764 (24) Net income (loss) $ (151,270) (376,384) (534,194) Net income (loss) attributable to noncontrolling interests (88,013) (227,678) (344,837) Net income (loss) attributable to GoHealth, Inc. $ (63,257) $ (148,706) $ (189,357) Non-GAAP financial measures: EBITDA $ 24,104 $ (211,549) $ (393,206) Adjusted EBITDA $ 75,091 $ (129,776) $ 33,821 Adjusted EBITDA margin 10.2 % (20.5) % 3.2 % The following is our net revenues and results thereof for the twelve months ended December 31, 2023 and 2022: Net revenues Twelve months ended Dec. 31, 2023 2022 $ Change % Change $ 734,671 $ 631,675 $ 102,996 16.3 % The $103.0 million, or 16.3% increase compared to the prior year period was primarily attributable to an increase in non-agency revenue, which reflects our investment in enrollment and engagement service offerings along with the $110.3 million negative revenue adjustment in the prior year.
Marketing and advertising costs are expensed and generally paid as incurred and since commission revenue is recognized upon approval of a submission but commission payments are paid to us over time, there are working capital requirements to fund the upfront cost of acquiring new policies.
Marketing and advertising costs are expensed and generally paid as incurred and since commissions revenue is recognized upon approval of a submission but commission payments are paid to us over time, there are working capital requirements to fund the upfront cost of acquiring new policies.
Sales Per Submission Medicare Segments Revenue per Submissions represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period, as reported above.
Sales Per Submission Sales per Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period, as reported above.
The accounting estimates and judgments related to the recognition of revenue require us to make assumptions about numerous factors, such as the determination of performance obligations and determination of the transaction price.
The accounting estimates and judgments related to the recognition of commission revenue require us to make assumptions about numerous factors, such as the determination of performance obligations and determination of the transaction price.
Liabilities Pursuant to TRAs In connection with the IPO, the Company entered into the Tax Receivable Agreement with GHH, LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of LLC Interests directly from GHH, LLC and the partial redemption of LLC Interests by GHH, LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of LLC Interests for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by GHH, LLC; and (3) certain additional tax benefits arising from payments made under the Tax Receivable Agreement.
Liabilities Pursuant to the TRA In connection with the IPO, the Company entered into the TRA with GHH, LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of LLC Interests directly from GHH, LLC and the partial redemption of LLC Interests by GHH, LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of LLC Interests for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by GHH, LLC; and (3) certain additional tax benefits arising from payments made under the TRA.
With leading proprietary technology and consumer insights, our end-to-end Encompass Solution offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence.
With leading proprietary technology and consumer insights, our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence.
Using machine learning technology, our agents aim to effectively qualify and match individuals with the best plan. This combination of technology and experienced agents delivers a personalized matching process that incorporates consumers’ top priorities and helps them to understand associated tradeoffs across various benefits as they select and enroll in a plan.
Using machine learning technology, our agents aim to effectively qualify and match individuals with the best plan through our PlanFit Tool. This combination of technology and experienced agents delivers a personalized matching process that incorporates consumers’ top priorities and helps them to understand associated tradeoffs across various benefits as they select and enroll in a plan.
GoHealth, Inc. is subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of GoHealth Holdings, LLC and is taxed at the prevailing corporate tax rates.
GoHealth, Inc. is subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of GHH, LLC and is taxed at the prevailing corporate tax rates.
Critical Accounting Policies and Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities in our financial statements. We regularly assess these estimates; however, actual amounts could differ from those estimates.
Critical Accounting Policies and Estimates The preparation of Consolidated Financial Statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and the disclosure of contingent assets and liabilities. We regularly assess these estimates; however, actual amounts could differ from those estimates.
GoHealth, Inc. 2022 Form 10-K 45 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2022 compared to fiscal year 2021.
GoHealth, Inc. 2023 Form 10-K 45 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2023 compared to fiscal year 2022.
We utilize the expected value approach to do this, incorporating a combination of historical lapse and premium increase data, available industry and health plan partner experience data, historical payment data by segment and health plan partner, as well as current forecast data to estimate forecasted renewal considerations, and then to constrain revenue recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.
We utilize the expected value approach to do this, incorporating a combination of historical lapse and premium increase data, available industry and health plan partner experience data, historical payment data by health plan partner, as well as current forecast data to estimate forecasted renewal commissions, and then to constrain commission revenue recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2022, is as follows: The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2023, is as follows: The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes. The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future.
The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes. The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character and timing of the taxable income of the Company in the future.
During the year ended December 31, 2022 and 2021, the Company was actively looking to terminate or sublease certain office spaces and call centers that were deemed no longer economically beneficial to the Company. As a result, these properties are considered individual asset groups for the purpose of testing for impairment.
During the twelve months ended December 31, 2023, 2022 and 2021, the Company was actively looking to terminate or sublease certain office spaces and call centers that were deemed no longer economically beneficial to the Company. As a result, these properties are considered individual asset groups for the purpose of testing for impairment.
If the Company determines that it will not be able to fully utilize all or part of the related tax benefits, the Company would reduce the portion of the Tax Receivable Agreement liability related to the tax benefits not expected to be utilized through earnings at that time.
If the Company determines that it will not be able to fully utilize all or part of the related tax benefits, the Company would reduce the portion of the TRA liability related to the tax benefits not expected to be utilized through earnings at that time.
Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1 st to March 31 st , commission revenue and Encompass revenue are typically second highest in our first quarter. The second and third quarters are known as special election periods and are our seasonally smallest quarters.
Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1 st to March 31 st , Medicare Submissions are typically second-highest in our first quarter. The second and third quarters are known as special election periods and are our seasonally smallest quarters.
In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including revenue growth and operating margins, among others. The projection of future taxable income involves judgement and actual taxable income may differ from our estimates, which could impact the timing of payments under the Tax Receivable Agreement.
In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including revenue growth and operating margins, among others. The projection of future taxable income involves judgement and actual taxable income may differ from our estimates, which could impact the timing of payments under the TRA.
A discussion and analysis regarding our results of operations for fiscal year 2021 compared to fiscal year 2020 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on March 16, 2022.
A discussion and analysis regarding our results of operations for fiscal year 2022 compared to fiscal year 2021 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on March 23, 2023.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 94,057 $ 94,056 $ 1 — % 14.9% 8.9% Amortization of intangible assets expense was $94.1 million for both the twelve months ended December 31, 2022 and 2021, and relates to the amortization of developed technology and customer relationships.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 94,057 $ 94,057 $ — — % 12.8% 14.9% Amortization of intangible assets expense was $94.1 million for both the twelve months ended December 31, 2023 and 2022, and relates to the amortization of developed technology and customer relationships.
Recent Accounting Pronouncements For a discussion of new accounting pronouncements recently adopted and not yet adopted, see Note 1. “Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K. Liquidity and Capital Resources Overview Our liquidity needs primarily include working capital and debt service requirements.
Recent Accounting Pronouncements For a discussion of new accounting pronouncements recently adopted, see Note 1. “Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K. Liquidity and Capital Resources Overview GoHealth, Inc. 2023 Form 10-K 51 Our liquidity needs primarily include working capital and debt service requirements.
There are limitations to the use of the non-GAAP financial measures presented in this Annual Report on Form 10-K. For example, our non- GoHealth, Inc. 2022 Form 10-K 48 GAAP financial measures may not be comparable to similarly titled measures of other companies.
There are limitations to the use of the non-GAAP financial measures presented in this Annual Report on Form 10-K. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies.
These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.
These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA; Adjusted EBITDA margin; Sales per Submission; Cost per Submission and Adjusted Gross Margin per Submission. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2022, 2021, and 2020 were 61.1%, 67.0% and 73.8%, respectively.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2023, 2022, and 2021 were 58.2%, 61.1% and 67.0%, respectively.
Significant management judgments and estimates must be made in connection with determination of the revenue to be recognized in any accounting period. If we made different judgments or utilized different estimates for any period, material differences in the amount and timing of revenue recognized could result.
Significant management judgments and estimates must be made to determine the commission revenue to be recognized in any accounting period. If we made different judgments or utilized different estimates for any period, material differences in the amount and timing of commission revenue recognized could result.
The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis.
The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for the most directly comparable measures prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis.
Marketing and advertising expenses are generally higher in the fourth quarter during the Medicare annual enrollment period, but because commissions from approved customers are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of applications submitted during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of applications submitted during the fourth quarter.
Marketing and advertising expenses are generally higher in the fourth quarter during AEP, but because commissions from approved customers are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of Submissions during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of Submissions during the fourth quarter.
At December 31, 2022, cash and cash equivalents totaled $16.5 million. We believe that our current sources of liquidity, which include cash and cash equivalents and funds available under the Credit Facilities, as described further below, will be sufficient to meet our projected operating and debt service requirements for at least the next 12 months.
At December 31, 2023, cash and cash equivalents totaled $90.8 million. We believe that our current sources of liquidity, which include cash and cash equivalents and funds available under the Credit Facilities, as described further below, will be sufficient to meet our projected operating and debt service requirements for at least the next twelve months.
As a result, we experience an increase in the number of submitted Medicare-related applications during the fourth quarter and an increase in expense related to the Medicare segments during the third and fourth quarters.
As a result, we experience an increase in the number of Submissions during the fourth quarter and an increase in expense related to the Medicare Submissions during the third and fourth quarters.
The accounting policies we believe to reflect our more significant estimates, judgments and assumptions that are most critical to understanding and evaluating our reported financial results are: • Revenue recognition and commissions receivable; • Share-based compensation; • Goodwill and intangible assets; • Impairment of operating lease ROU assets; • Income taxes; and • Liabilities pursuant to tax receivable agreements (“TRAs”).
The accounting policies we believe to reflect our more significant estimates, judgments and assumptions that are most critical to understanding and evaluating our reported financial results are: • Commission revenue recognition and commissions receivable; • Share-based compensation; • Intangible assets; • Impairment of operating lease ROU assets; • Liabilities pursuant to the TRA.
GoHealth, Inc. 2022 Form 10-K 57 Revenue Recognition and Commissions Receivable In accordance with ASC 606, Revenue from Contracts with Customers , revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services.
Commission Revenue Recognition and Commissions Receivable In accordance with ASC 606, Revenue from Contracts with Customers , revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services.
As of December 31, 2022, the Company has determined that a $0.6 million liability related to the Tax Receivable Agreement arose from the Transactions. Should the Company determine that any additional Tax Receivable Agreement liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time.
As of December 31, 2023 and December 31, 2022, the Company determined that a $0.8 million and $0.6 million liability related to the TRA arose from the Transactions, respectively. Should the Company determine that any additional TRA liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time.
The fair values were estimated using a discounted cash flows approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
GoHealth, Inc. 2023 Form 10-K 55 The fair values were estimated using a discounted cash flow approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
The uncertainty associated with the variable consideration is subsequently resolved when the policy terminates. Commissions receivable includes the variable consideration for policies that may renew, and therefore, are subject to the same assumptions, judgments and estimates used when recognizing revenue as noted above.
The uncertainty associated with the variable consideration is subsequently resolved when the policy terminates. Commissions receivable includes the variable consideration for policies that may renew, and therefore, are subject to the same assumptions, judgments and estimates used when recognizing commission revenue as noted above. See Note 10, “Revenue,” for further discussion of commission revenue and commissions receivable.
As a result, GoHealth, Inc. consolidates GoHealth Holdings, LLC and records significant GoHealth, Inc. 2022 Form 10-K 44 non-controlling interests in a consolidated entity in GoHealth, Inc.’s Consolidated Financial Statements for the economic interest in GoHealth Holdings, LLC held directly or indirectly by the Continuing Equity Owners.
As a result, GoHealth, Inc. consolidates GHH, LLC and records significant non-controlling interest in a consolidated entity in GoHealth, Inc.’s Consolidated Financial Statements for the economic interest in GHH, LLC held directly or indirectly by the Continuing Equity Owners.
By working closely with our benefit consultants and dedicated health plan enrollment specialists, individuals can better understand the plan options available and receive more detailed, plan-specific information during the enrollment process. Coupled with the execution of our new member onboarding action plans, beneficiaries who enroll through our Encompass Solution exhibit higher customer persistency.
By working closely with our benefit consultants and dedicated health plan enrollment specialists, we believe individuals can better understand the plan options available and receive more detailed, plan-specific information during the enrollment process. Coupled with the execution of our new member onboarding action plans, consumers who enroll through our Encompass model have exhibited higher consumer persistency.
The following table presents a summary of cash flows for the twelve months ended December 31, 2022, 2021, and 2020; Twelve months ended Dec. 31, (in thousands) 2022 2021 2020 Net cash provided by (used in) operating activities $ 60,904 $ (299,006) $ (114,217) Net cash used in investing activities $ (13,512) $ (19,801) $ (14,523) Net cash (used in) provided by financing activities $ (115,051) $ 259,089 $ 260,663 Operating Activities GoHealth, Inc. 2022 Form 10-K 54 Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, goodwill impairment charges, loss on extinguishment of debt, operating lease impairment charges, non-cash restructuring charges; non-cash lease expense and the effect of changes in working capital and other activities.
The following table presents a summary of cash flows for the twelve months ended December 31, 2023, 2022, and 2021; Twelve months ended Dec. 31, (in thousands) 2023 2022 2021 Net cash provided by (used in) operating activities $ 109,141 $ 60,904 $ (299,006) Net cash used in investing activities $ (13,732) $ (13,512) $ (19,801) Net cash (used in) provided by financing activities $ (21,106) $ (115,051) $ 259,089 Operating Activities Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, goodwill and intangible impairment charges, operating lease impairment charges, non-cash restructuring charges, non-cash lease expense and the effect of changes in working capital and other activities.
Sales/Cost of Submission GoHealth, Inc. 2022 Form 10-K 53 Medicare Segments Sales/Cost of Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the cost to convert a prospect into a Submission (comprised of cost of revenue, marketing and advertising expenses and customer care and enrollment expenses) for such period.
Sales/Cost of Submission and Cost Per Submission Sales/Cost of Submission represents (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, and such expenses related to our Non-Encompass BPO Services, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the aggregate cost to convert prospects into Submissions (comprised of revenue share, marketing and advertising expenses and customer care and enrollment expenses, excluding associated share-based compensation expense, the impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, and such expenses related to our Non-Encompass BPO Services) for such period.
There are GoHealth, Inc. 2022 Form 10-K 59 additional estimates and assumptions used to arrive at estimated future cash flows, including discount rate, downtime, abatement, and commissions.
There are additional estimates and assumptions used to arrive at estimated future cash flows, including discount rate, downtime, abatement and commissions.
Submissions Medicare Segments Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our dedicated services programs where GoHealth-employed agents are dedicated to certain health plan partners and agencies we partner with or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
Submissions Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
Ownership GoHealth, Inc. is the sole managing member of GoHealth Holdings, LLC. Although we have a minority economic interest in GoHealth Holdings, LLC, we have the sole voting interest in, and control of the business and affairs of, GoHealth Holdings, LLC and its direct and indirect subsidiaries.
Although we have a minority economic interest in GHH, LLC, we have the sole voting interest in, and control of the business and affairs of, GHH, LLC and its direct and indirect subsidiaries.
The fair value of RSUs and performance-based PSUs are determined based on the stock price on the date of grant. The fair value of stock options is calculated using a Black-Scholes-Merton pricing model. Embedded in the pricing model are several assumptions, including the expected life of the award, the expected dividend yield, the risk-free interest rate and the expected volatility.
Embedded in the simulation are several assumptions, including the expected life of the award, expected dividend yield, the risk-free interest rate and the expected volatility. The fair value of RSUs and performance-based PSUs are determined based on the closing stock price on the grant date.
(8) Represents the loss on debt extinguishment related to the Initial Term Loan Facility. (9) Represents goodwill impairment charges related to the Medicare— Internal and Medicare— External reporting units for the twelve months ended December 31, 2021.
(8) Represents the loss on debt extinguishment related to the Initial Term Loan Facility. (9) Represents indefinite-lived intangible asset impairment charges for the twelve months ended December 31, 2023 and the goodwill impairment charges for the twelve months ended December 31, 2021.
Not all Submissions will go into effect, as some individuals may fail to enroll or once enrolled may switch out of a policy within the disenrollment period during the first 90 days of the policy. The following tables present the number of Submissions by product for each of the Medicare segments for the periods presented.
Not all Submissions will go into effect, as some individuals may fail to enroll or once enrolled may switch out of a policy within the disenrollment period during the first 90 days of the policy.
As of December 31, 2022, the Company had a principal amount of $113.7 million, $305.4 million, and $99.0 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. The Incremental Term Loan Facility effective interest rate was 11.2% and 7.5% at December 31, 2022 and 2021, respectively.
Term Loan Facilities As of December 31, 2023, the Company had a principal amount of $110.4 million, $296.3 million, and $96.1 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. The Incremental Term Loan Facility effective interest rate was 13.0% and 11.2% at December 31, 2023 and 2022, respectively.
Share-Based Compensation We recognize compensation expense for all share-based awards, including time-vesting and performance-vesting profit units (collectively, “Profit Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”), and stock appreciation rights ("SARs") based on the estimated grant date fair value of awards.
Share-Based Compensation We grant share-based awards to employees and non-employee directors. Share-based awards include time-vesting profits units (“Time-Vesting Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”) and stock appreciation rights ("SARs").We recognize compensation expense for all share-based awards based on the estimated grant date fair value.
Impairment of Operating Lease ROU Assets The Company reviews operating lease ROU assets, in conjunction with other long-lived assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable.
See Note 4 "Goodwill and Intangible Assets, Net" for further discussion of our intangible assets. Impairment of Operating Lease ROU Assets The Company reviews operating lease right-of-use (“ROU”) assets, in conjunction with other long-lived assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable.
Net cash provided by operating activities was $60.9 million for the twelve months ended December 31, 2022, compared to cash used in operating activities of $299.0 million for the twelve months ended December 31, 2021.
Net cash provided by operating activities was $109.1 million for the twelve months ended December 31, 2023, compared to $60.9 million for the twelve months ended December 31, 2022.
The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: Twelve months ended Dec. 31, Non-GAAP Financial Measures 2022 2021 2020 Net revenues $ 631,675 $ 1,062,415 $ 877,350 Net income (loss) (376,384) (534,194) (97,200) Interest expense 57,069 33,505 32,969 Income tax expense (benefit) 764 (24) 43 Depreciation and amortization expense 107,002 107,507 98,552 EBITDA (211,549) (393,206) 34,364 Share-based compensation expense (1) 32,124 27,297 6,929 Operating lease impairment charges (2) 25,345 1,062 — Restructuring and other related charges (3) 12,184 — — Professional services (4) 4,752 — — Severance costs (5) 3,340 — 77 Legal fees (6) 3,478 180 — Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement (7) 550 — — Loss on extinguishment of debt (8) — 11,935 — Goodwill impairment charges (9) — 386,553 — Accelerated vesting of certain equity awards (10) — — 209,300 Change in fair value of contingent consideration liability (11) — — 19,700 IPO transactions costs (12) — — 659 Adjusted EBITDA $ (129,776) $ 33,821 $ 271,029 Adjusted EBITDA margin (20.5) % 3.2 % 30.9 % (1) Represents non-cash share-based compensation expense relating to equity awards, as well share-based compensation expense relating to liability classified awards that will be settled in cash.
The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: GoHealth, Inc. 2023 Form 10-K 48 Twelve months ended Dec. 31, Non-GAAP Financial Measures 2023 2022 2021 Net revenues $ 734,671 $ 631,675 $ 1,062,415 Net income (loss) (151,270) (376,384) (534,194) Interest expense 69,472 57,069 33,505 Income tax expense (benefit) 154 764 (24) Depreciation and amortization expense 105,748 107,002 107,507 EBITDA 24,104 (211,549) (393,206) Share-based compensation expense (benefit) (1) 19,564 32,124 27,297 Legal fees (2) 14,840 3,478 180 Operating lease impairment charges (3) 2,687 25,345 1,062 Severance costs (4) 1,920 3,340 — Professional services (5) 1,548 4,752 — Restructuring and other related charges (6) — 12,184 — Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement (7) 428 550 — Loss on extinguishment of debt (8) — — 11,935 Goodwill and intangible asset impairment charges (9) 10,000 — 386,553 Adjusted EBITDA $ 75,091 $ (129,776) $ 33,821 Adjusted EBITDA margin 10.2 % (20.5) % 3.2 % (1) Represents non-cash share-based compensation expense (benefit) relating to equity awards as well share-based compensation expense (benefit) relating to liability classified awards that will be settled in cash.
Persistency-adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period. Sales per Submission represents revenues only from policies sold during the period, but excludes policies originally submitted in prior periods.
Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period.
Additionally, the Company made the strategic decision to exit its non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass Solution, to focus on its core business.
GoHealth, Inc. 2023 Form 10-K 44 Additionally, the Company made the strategic decision to exit its non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. The exit was completed during the second quarter of 2023.
GoHealth, Inc. 2022 Form 10-K 47 Operating lease impairment charges Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 25,345 $ 1,062 $ 24,283 2286.5 % 4.0% 0.1% As part of our continued cost savings initiatives, we are actively looking to terminate or sublease certain office spaces and call centers.
Operating lease impairment charges Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 2,687 $ 25,345 $ (22,658) (89.4) % 0.4% 4.0% As part of our continued cost savings initiatives, we are actively looking to terminate or sublease certain office spaces and call centers.
Investing Activities Net cash used in investing activities decreased to $13.5 million for the twelve months ended December 31, 2022, from $19.8 million for the twelve months ended December 31, 2021. The decrease was primarily driven by a decrease in purchases of property and equipment and a decrease in capitalized internal-use software related to new technology, software, and systems.
Investing Activities Net cash used in investing activities increased to $13.7 million for the twelve months ended December 31, 2023, from $13.5 million for the twelve months ended December 31, 2022. The change was driven by an increase in capitalized internal-use software related to new technology, software and systems.
Restructuring and other related charges Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 12,184 $ — $ 12,184 100.0 % 1.9% —% During the twelve months ended December 31, 2022, we implemented restructuring initiatives as part of our strategic transformation to drive efficiency and optimize costs.
GoHealth, Inc. 2023 Form 10-K 47 Restructuring and other related charges Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ — $ 12,184 $ (12,184) NM —% 1.9% _________________________ NM = Not meaningful During the second and third quarters of fiscal year 2022, we implemented restructuring initiatives as part of our strategic transformation to drive efficiency and optimize costs.
Aggregate commissions is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions per commissionable Submissions, and this figure excludes commissions through dedicated services programs where GoHealth-employed agents are dedicated to certain health plan partners and agencies we partner with.
Aggregate commissions are equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions per commissionable Submissions, and this figure excludes commissions through our Non-Encompass BPO Services.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. We assume no obligation to update any of these forward-looking statements. Unless otherwise noted, all dollars are in thousands.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. The risks and uncertainties described in this 2023 Annual Report on Form 10-K are not the only risks and uncertainties we face.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2022 and 2021: Cost of revenue Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 187,670 $ 239,335 $ (51,665) (21.6) % 29.7% 22.5% The $51.7 million, or 21.6%, decrease was primarily attributable to a $29.6 million increase in the cost of revenue impact of negative revenue adjustments relating to performance obligations satisfied in prior periods as well as declines in certain direct partner campaigns with revenue-sharing components, resulting in a decrease in cost of revenue.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2023 and 2022: Revenue share Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 158,961 $ 187,670 $ (28,709) (15.3) % 21.6% 29.7% The $28.7 million, or 15.3% decrease was primarily attributable to declines in certain direct partner campaigns with revenue-sharing components.
As of December 31, 2022, the Company had no amounts outstanding under the Revolving Credit Facilities and had a remaining capacity of $200.0 million. To the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds, which may include the sale of equity securities or through debt financing arrangements.
To the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds, which may include the sale of equity securities or through debt financing arrangements.
In certain cases, numbers and percentages in the tables below may not foot due to rounding. Overview We are a leading health insurance marketplace and Medicare-focused digital health company whose mission is to improve access to healthcare in America.
In certain cases, numbers and percentages in the tables below may not foot due to rounding. Overview We are a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life.
Technology expense Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 46,094 $ 48,429 $ (2,335) (4.8) % 7.3% 4.6% The $2.3 million, or 4.8%, decrease was primarily attributable to reduced headcount in our technology support functions during the year.
Technology expense Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 43,302 $ 46,094 $ (2,792) (6.1) % 5.9% 7.3% The $2.8 million, or 6.1% decrease was primarily attributable to reduced headcount in our technology support functions, partially offset by the third quarter technological enhancements in preparation for the 2023 AEP.
Encompass Engage includes post-enrollment member outreach and engagement services. Our agents strive to alleviate the confusion that beneficiaries often feel by facilitating an onboarding experience customized to a members’ plan and health needs.
During the second quarter of 2023, we expanded our Encompass Connect contracts and model to include our external partners, which we refer to as our vConnect program. Encompass Engage includes post-enrollment member outreach and engagement services. Our agents strive to alleviate the confusion that consumers often feel by facilitating an onboarding experience customized to a member’s plan and health needs.
The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency-adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period.
Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue GoHealth, Inc. 2023 Form 10-K 50 would not be expected to occur. These factors may result in varying values from period to period.
Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this Annual Report on Form 10-K. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented.
Reconciliations of each of EBITDA, Adjusted EBITDA, Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission to its most directly comparable GAAP financial measure, are presented in the tables below in this Annual Report on Form 10-K.
Marketing and advertising expense Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 207,559 $ 365,141 $ (157,582) (43.2) % 32.9% 34.4% The $157.6 million, or 43.2%, decrease was primarily attributable to an intentional pullback on marketing and advertising spend as we focused on cash flow optimization.
Marketing and advertising expense Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 205,042 $ 207,559 $ (2,517) (1.2) % 27.9% 32.9% The $2.5 million, or 1.2% decrease was primarily attributable to an intentional pullback on marketing and advertising spend as the Company focused on higher quality Submissions through targeted marketing.
In addition to tax expenses, we also incur expenses related to our status as a public company, plus payment obligations under the Tax Receivable Agreement, which could be significant.
In addition to tax expenses, we also incur expenses related to our status as a public company, plus payment obligations under the Tax Receivable Agreement (“TRA”), which could be significant. We intend to cause GHH, LLC to make distributions to us in an amount sufficient to allow us to pay these expenses and fund any payments due under the TRA.
Our proprietary technology platform leverages modern machine-learning algorithms powered by nearly two decades of insurance behavioral data to reimagine the optimal process for helping individuals find the best health insurance plan for their specific needs.
Our proprietary technology platform leverages modern machine-learning algorithms powered by over two decades of insurance behavioral data to reimagine the optimal process for helping consumers find the best health plan for their specific needs. Our unbiased, technology-driven marketplace and highly-trained agents have enabled us to enroll millions of people in Medicare and individual and family plans since our inception.
Intangible assets subject to amortization are also evaluated for impairment when indicators of impairment are determined to exist. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition.
Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If such review indicates that the carrying amount of intangible assets is not recoverable, the carrying amount of such assets is reduced to fair value.
Borrowings under the Class A Revolving Commitments bear interest at either ABR plus 5.50% per annum or LIBOR plus 6.50% per annum. Borrowings under the Class B Revolving Commitments bear interest at either ABR plus 3.00% per annum or LIBOR plus 4.00% per annum.
The New Class A Revolving Commitments mature on June 30, 2025 and bear interest at either ABR plus 5.50% per annum or SOFR plus 6.50% per annum. The Remaining Class B Revolving Commitments continue to mature on September 13, 2024 and bear interest at either ABR plus 3.00% per annum or SOFR plus 4.00% per annum.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2022 2021 $ Change % Change 2022 2021 $ 116,530 $ 98,183 $ 18,347 18.7 % 18.4% 9.2% The $18.3 million, or 18.7%, increase was primarily attributable to a $7.7 million increase in share-based compensation expense, a $5.2 million increase in consulting fees, and $2.2 million of executive severance expense.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2023 2022 $ Change % Change 2023 2022 $ 93,069 $ 116,530 $ (23,461) (20.1) % 12.7% 18.4% The $23.5 million, or 20.1% decrease was primarily attributable to an $11.4 million decrease in share-based compensation expense a $7.6 million decrease in expense related to employee incentive compensation, a $3.7 million decrease in expenses related to consulting fees, a $3.3 million decrease in expenses related to corporate insurance and a $2.5 million decrease in depreciation expense, partially offset by a $7.5 million increase in expenses related to legal fees.
In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.
We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-routine items.
The Borrower is required to pay a commitment fee of 0.50% per annum under the Revolving Credit Facilities. The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of December 31, 2022.
The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of both December 31, 2023 and December 31, 2022. The Revolving Credit Facilities had a remaining capacity of $200.0 million in the aggregate as of both December 31, 2023 and December 31, 2022.
Amendment No. 5, as described above, also separates the Revolving Credit Facilities into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million and Class B Revolving Commitments in the amount of $170.0 million.
Revolving Credit Facilities The Company collectively refers to the Revolving Credit Facility, the Incremental Revolving Credit Facilities, and the Incremental No. 4 Revolving Credit Facility as the “Revolving Credit Facilities.” The Revolving Credit Facilities are separated into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million and Class B Revolving Commitments in the amount of $170.0 million before the signing of Amendment No. 11 in March 2024.
During second quarter of 2021, we recorded a $1.1 million operating lease impairment charge related to a sublease agreement entered into during the twelve months ended December 31, 2021. We continue to evaluate our portfolio of properties, and, therefore, it is possible that impairments could be identified in future periods, and such amounts could be material.
We continue to evaluate our portfolio of properties, and, therefore, it is possible that impairments could be identified in future periods, and such amounts could be material.
(4) Represents costs associated with non-recurring consulting fees and other professional services. (5) Represents costs associated with the termination of employment and associated fees unrelated to restructuring activities. (6) Represents non-recurring legal fees unrelated to our core operations. (7) Represents expense related to the measurement of our Tax Receivable Agreement obligation.
(5) Represents costs associated with non-routine consulting fees and other professional services. (6) Represents employee termination benefits and other associated costs related to restructuring activities, as described in Note 14. “ Restructuring Costs” of the Notes to Consolidated Financial Statements. (7) Represents expense related to the measurement of our TRA obligation.
The Company is forecasting to increase its investment in developing technologies to support the continued growth in the Encompass Solution. Financing Activities Net cash used in financing activities was $115.1 million for the twelve months ended December 31, 2022, from net cash provided by financing activities of $259.1 million for the twelve months ended December 31, 2021.
Financing Activities Net cash used in financing activities was $21.1 million for the twelve months ended December 31, 2023, from net cash used in financing activities of $115.1 million for the twelve months ended December 31, 2022.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options, and PSUs are recognized on a straight-line basis over the requisite service or performance period, which is generally three to five years. Effective September 13, 2019 and in conjunction with the Centerbridge Acquisition, the Company authorized the grants of non-voting Profit Units.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options and PSUs are recognized on a straight-line GoHealth, Inc. 2023 Form 10-K 54 basis over the requisite service or performance period, which is generally three to five years. We recognize forfeitures as they occur. The fair value of Time-Vesting Units and market-based PSUs are determined using a Monte Carlo simulation.
In response to these market pressures, during 2022, the Company focused its efforts on delivering efficiency, with an emphasis on optimization as opposed to revenue maximization.
In response to the pressures on LTVs in 2021 and 2022 that we discussed in our 2022 Annual Report on Form 10-K, we focused our efforts on delivering efficiency, with an emphasis on operational efficiency as opposed to revenue maximization.
(2) Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values. (3) Represents employee termination benefits and other associated costs related to restructuring activities, as described in Note 15. “ Restructuring Costs” of the Notes to Consolidated Financial Statements.
(2) Represents non-routine legal fees, settlement accruals and other expenses unrelated to our corporate operations. (3) Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values. (4) Represents costs associated with the termination of executive employment and associated fees unrelated to restructuring activities.
There was no impairment of goodwill for the twelve months ended December 31, 2020. Indefinite-lived intangible assets are tested for impairment on November 30 th of each year or whenever events or changes in circumstances indicate that an impairment may exist.
Intangible Assets Our trade names asset is an indefinite-lived intangible asset tested for impairment on November 30 th of each year or whenever events or changes in circumstances indicate that an impairment may exist. If the carrying amount of our indefinite-lived intangible trade names exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.
Update on Business Trends and Strategy The Company is part of a dynamic market and, as expectations evolve, the Company likewise works to evolve in parallel its business strategies and priorities. The pressures on LTVs in 2021 that we previously observed and discussed have continued throughout 2022, as beneficiaries appear to change plans more frequently.
Update on Business Trends and Strategy GoHealth is part of a dynamic market and, as expectations evolve, we likewise work to evolve our business strategies and priorities in parallel.
The following are our Sales/Cost of Submission as well as our Cost of Submission, for our Medicare segments for the twelve months ended December 31, 2022 and 2021: Twelve months ended Dec. 31, 2022 2021 2020 Sales/Cost of Submission $ 1.3 $ 1.1 $ 1.4 Cost of Submission $ 589,985 $ 781,515 $ 416,202 The increase in Sales/Cost of Submission is attributable to our strategic shift towards the Encompass model with improved operating efficiencies.
The increase in Sales/Cost of Submission, the decrease in Cost of Submission and decrease in Cost per Submission for the twelve months ended December 31, 2023 compared to the prior year period was primarily attributable to our strategic shift towards the Encompass operating model with improved operating efficiencies.